# rAd-p53 Gene Therapy for Advanced Malignant Thyroid Tumors

> **NCT00902122** · PHASE4 · UNKNOWN · sponsor: **Shenzhen SiBiono GeneTech Co.,Ltd** · enrollment: 600 (estimated)

## Conditions studied

- Advanced Malignant Thyroid Tumors

## Interventions

- **DRUG:** rAd-p53 gene
- **PROCEDURE:** surgery
- **DRUG:** p53 gene therapy
- **RADIATION:** p53 gene therapy with radioactive iodine

## Key facts

- **NCT ID:** NCT00902122
- **Lead sponsor:** Shenzhen SiBiono GeneTech Co.,Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2009-05
- **Primary completion:** 2012-08
- **Final completion:** 2012-08
- **Target enrollment:** 600 (ESTIMATED)
- **Last updated:** 2012-04-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00902122

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00902122, "rAd-p53 Gene Therapy for Advanced Malignant Thyroid Tumors". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT00902122. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*